|Bid||1,370.00 x 0|
|Ask||1,384.00 x 0|
|Day's range||1,360.86 - 1,384.00|
|52-week range||1,284.00 - 1,847.00|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||10.93|
|Earnings date||03 Feb 2021|
|Forward dividend & yield||0.76 (5.51%)|
|Ex-dividend date||12 Nov 2020|
|1y target est||1,644.50|
The coronavirus pandemic has impacted lots of industries but it didn't slow down the pace of new drug approvals. The FDA greenlighted 59 new drugs last year, and 2021 is shaping up to be a big year too. Read on to see why new drugs from GlaxoSmithKline (NYSE: GSK), Gilead Sciences (NASDAQ: GILD), and Eli Lilly (NYSE: LLY) made the list.
Roland Head explains how he plans to use FTSE 100 dividend stocks to provide a reliable retirement income. These two shares both yield over 5.5%. The post I’d buy these 2 FTSE 100 dividend stocks to retire on a passive income appeared first on The Motley Fool UK.
The falling GlaxoSmithKline share price makes today's valuation look attractive, and the generous 5.86% yield is also tempting. So what's my problem? The post Should I ignore the falling GlaxoSmithKline share price and pocket its 6% yield anyway? appeared first on The Motley Fool UK.